BNET Industries

Market Cap:$6.6M
Last Fiscal Year Sales:$2.6M
  • Public
  • US
Dow Jones Description

Acusphere, Inc. is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microsphere technology. We are focused on developing proprietary drugs that can offer significant benefits such as improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost.

President, Chief Executive Officer and DirectorSherri C. Oberg
Number of Employees 118
Contact Information

500 Arsenal St

Watertown, Massachusetts 02472

www.acusphere.c...

1 617 648 8800

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Acusphere Announces Publication of Imagify Phase 3 Trials in the European Journal of Echocardiography

    1/25/09 - Board Member - Entering - View Story

  • Acusphere, Inc. Announces Resignation of Richard Walovitch

    1/07/09 - Mgmt. Change Leaving - Vice President - View Story

News & Analysis

acusphere inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Sherri C. Oberg President, Chief Executive Officer and Director
John F. Thero CFO & Senior Vice President
Lawrence Gyenes Senior Vice President and Chief Financial Officer
Howard Bernstein Executive Vice President, Research and Development
Charles Cox Senior Vice President, Corp Development & Marketing
Dennis Bucceri Senior Vice President of Regulatory Affairs
Michael Slater Senior Vice President, Operations
Nancy Wetherbee Senior Vice President, Business Development
Patrick Gallagher Joins Acusphere as Senior Vice President, Business Development
Richard Walovitch Senior Vice President, Clinical Res
Donald Chickering Vice President, Technical Operations, Process Development & Formulations
Frederick W Ahlholm Vice President of Finance
Jonathan Jaffe Vice President, Medical Affairs
Mona Haynes Vice President, Sales & Marketing
Thomas M. Hanlon Vice President, Manufacturing & Matls Management
Robert S. Langer Jr. co-founder
Rajeev A Jain Manager of Formulations Support and Pharmaceutics
William I Ramage Executive Consultant
Derek Lemke-Von Ammon Director
Garen G. Bohlin Director
Martyn D. Greenacre Director

Board of Directors

Name (plus bio) Position
Derek L. Ammon Board of Directors
Sandra L. Fenwick Board of Directors

Sherri C. Oberg, a co-founder of Acusphere, has served as our President and Chief Executive Officer and one of our directors since our inception in 1993. Prior to joining Acusphere, Ms. Oberg was President and Chief Executive Officer of Neomorphics, Inc., a venture capital backed company focused on tissue engineering, from 1991 to 1992. Prior to joining Neomorphics, she was a venture capitalist at Aegis Venture Funds from 1988 to 1991, and at Inco Venture Capital Management from 1986 to 1988. Ms. Oberg is a member of the Board of Overseers of The Amos Tuck School at Dartmouth College. Ms. Oberg holds a B.A. from Dartmouth College and an M.B.A. from the Amos Tuck School of Business Administration.

Organization Position Status
Acusphere, Inc. President, Chief Executive Officer and Director Current
Acusphere, Inc. Co-Founder Current
Tuck School of Business at Dartmouth M.B.A. Former
Dartmouth College B.A. Former
Organization Position Status
Acusphere, Inc. CFO & Senior Vice President Current
Acusphere, Inc. Board of Directors Current
ABIOMED, Inc. Chief Financial Officer Former
ABIOMED, Inc. Senior Vice President Finance, Treasurer Former
College of the Holy Cross B.A. in Economics, Accounting Former

Lawrence A. Gyenes has served as Senior Vice President, Chief Financial Officer and Secretary since October 2007 and as Treasurer since March 2008. From March 2007 to July 2007, Mr. Gyenes served as Chief Financial Officer of Zila, Inc. From March 2006 to February 2007, Mr. Gyenes provided independent healthcare financial consulting services primarily to investment management firms. From August 2004 to October 2005, Mr. Gyenes was Senior Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc. From July 2001 to July 2004, Mr. Gyenes was Chief Financial Officer of privately held Reliant Pharmaceuticals, Inc. From January 2001 to June 2001, Mr. Gyenes consulted on the divestiture of the DuPont Pharmaceuticals Company. Previously, Mr. Gyenes served as Chief Financial Officer of Rand McNally & Co., CompuServe Corporation and Helene Curtis, Inc. Mr. Gyenes spent 15 years in progressively more responsible positions with G. D. Searle & Co. completing his career there as Corporate Vice President, Finance responsible for the company's global finance and information technology functions. Mr. Gyenes has a B.S. in Accounting from the University of Illinois and an MBA from the University of Chicago.

Organization Position Status
Acusphere, Inc. Senior Vice President and Chief Financial Officer Current
Reliant Pharmaceuticals, Inc. Chief Financial Officer Former
Zila, Inc. Cfo Former
Rand McNally & Company Chief Financial Officer Former
Savient Pharmaceuticals, Inc. Chief Financial Officer Former
Compuserve Interactive Services, Inc. Chief Financial Officer Former
Savient Pharmaceuticals, Inc. Senior Vice President Former
University of Chicago Mba Former
University of Illinois Bachelor of Science In Accounting Former

Howard Bernstein, M.D., Ph.D. has served as Executive Vice President, Research and Development of the Company since February 2007, as Senior Vice President, Research and Development since January 2000 and as Vice President of Research and Development from 1994 to January 2000. Prior to joining the Company, Dr. Bernstein served as Vice President of Pharmaceutical Development at Alkermes, Inc. from 1992 to 1994 and as Vice President of Research at Enzytech Inc. from 1991 to 1992. Dr. Bernstein holds an M.D. from Harvard Medical School and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Organization Position Status
Acusphere, Inc. Executive Vice President, Research and Development Current
Acusphere, Inc. Senior Vice President, Res & Development Former
Alkermes, Inc. Vice President of Pharmaceutical Development Former
Massachusetts, Inc. Ph.D. In Chemical Engineering Former
Massachusetts Institute of Technology Ph.D. in Chemical Engineering Former
Harvard Medical School M.D. Former
Organization Position Status
Acusphere, Inc. Senior Vice President, Corp Development & Marketing Current
Organization Position Status
Acusphere, Inc. Senior Vice President of Regulatory Affairs Current

Mr. Slater has served as Senior Vice President, Operations at Acusphere since 2001. Prior to joining Acusphere, he was Vice President of Operations and Vice President of Quality Systems and Regulatory Affairs at Anika Therapeutics, Inc. Mr. Slater has also served as Vice President of Regulatory Affairs at Biogen, Inc., Director of Corporate Regulatory Affairs at Biogen S.A., an independent consultant to the biopharmaceutical industry, as well as Executive Vice President, Development Operations for ImmuLogic Pharmaceutical Corporation. While at Hoechst Pharmaceuticals he held various positions including Senior Manager, Medical Services. Mr. Slater holds a B.S. in Information Science from the Metropolitan University of Leeds, England.

Organization Position Status
Acusphere, Inc. Senior Vice President, Operations Current
Anika Therapeutics, Inc. Vice President of Quality Systems and Regulatory Affairs Former
Biogen, Inc. Vice President of Regulatory Affairs Former
Biogen Idec, Inc. Vice President of Regulatory Affairs Former
Biogen Idec, Inc. Director of Corporate Regulatory Affairs Former
Biogen, Inc. Consultant Former
Organization Position Status
Acusphere, Inc. Senior Vice President, Business Development Current
Gill Fishman Associates Current
Athena Diagnostics, Inc. Director of Marketing Former
Simmons College School of Management MBA Former
Mount Holyoke College B.A. degree in Biochemistry Former
Organization Position Status
Acusphere, Inc. Joins Acusphere as Senior Vice President, Business Development Current

Richard Walovitch, Ph.D. has served as Senior Vice President, Clinical Research of the Company since November 2005 and as Vice President, Clinical Research from March 1997 to November 2005. Prior to joining Acusphere, Dr. Walovitch was Vice President of Pre-clinical and Clinical Research at Epix Medical Inc. (formerly Metasyn) from 1993 to 1997 and the International Project Clinician at DuPont Merck Pharmaceutical Company from 1988 to 1993. Dr. Walovitch holds a B.S. in Biology and a Ph.D. in Pharmacology from the University of Illinois.

Organization Position Status
Acusphere, Inc. Senior Vice President, Clinical Res Current
University of Illinois Ph.D. in Pharmacology Former
University of Illinois B.S. In Biology Former
Organization Position Status
Acusphere, Inc. Vice President, Technical Operations, Process Development & Formulations Current
Acusphere, Inc. Senior Director of Process Development Current
Brown University Ph.D. In Medical Science Former
Rensselaer Polytechnic Institute Bachelors of Science Degree In Biomedical Engineering Former
Organization Position Status
Acusphere, Inc. Vice President of Finance Current
Organization Position Status
Acusphere, Inc. Vice President, Medical Affairs Current
Organization Position Status
Acusphere, Inc. Vice President, Sales & Marketing Current
Organization Position Status
Acusphere, Inc. Vice President, Manufacturing & Matls Management Current
Villanova University B.S. in Biology Former

Robert S. Langer, Sc.D., is one of 13 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written over 950 articles. He also has more than 600 issued or pending patents worldwide, one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the United States. Dr. Langer's patents have been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology and medical device companies; a number of these companies were launched on the basis of these patent licenses. He served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 -- 2002 and as Chairman from 1999-2002. Dr. Langer has received over 150 major awards. In 2007, he received the 2006 United States National Medal of Science. In 2002, he received the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers and the world's most prestigious engineering prize, from the National Academy of Engineering. He is also the only engineer to receive the Gairdner Foundation International Award; 68 recipients of this award have subsequently received a Nobel Prize.

Organization Position Status
Acusphere, Inc. co-founder Current
PureTech Ventures Co-Founder Current
Echo Therapeutics, Inc. Co-Founder Current
Gelesis Inc. Co-Founder, Partner Current
Alseres Pharmaceuticals, Inc. Professor Current
Massachusetts Institute Institute Prof Current
Massachusetts Institute of Technology Professor Current
Wyeth Current
RD Legal Funding LLC Current
Analysis Group, Inc. Current
NYSE Group, Inc. Current
Fda.Com Chairman Current
U.S. Genomics, Inc. Board of Directors Current
Echo Therapeutics, Inc. Director Current
Alseres Pharmaceuticals, Inc. Director Current
Redchip Companies, Inc. Board of Directors Current
PureTech Ventures Venture Partner Former
Echo Therapeutics, Inc. Director and Chairman of the Scientific Advisory Board Former
Guilford Pharmaceuticals, Inc. Director Former
Alkermes, Inc. Director Former
Momenta Pharmaceuticals, Inc. Board of Directors Former
Warner-Lambert Director Former
Massachusetts Institute of Technology Ph.D. Former
Cornell University B.S. Former
Massachusetts Institute of Technology Sc.D. in Chemical Engineering Former
U.S. Food and Drug Administration member Former
Organization Position Status
Acusphere, Inc. Manager of Formulations Support and Pharmaceutics Current

William I. Ramage, D. Phil., has served as an Executive Consultant at Acusphere since 2000 and as an Independent Business Development and Strategic Marketing Consultant to us from 1999 to 2000 and to other clients since 1998. Prior to Acusphere, Dr. Ramage was Vice President Business Development and Marketing at Molecular BioSystems from 1996 to 1998, and Vice President Business Development and Customer Services at DuPont Merck, a leader in nuclear imaging agents for myocardial perfusion imaging, from 1995 to 1996. Dr. Ramage holds a B.Sc. from the University of Glasgow and a D.Phil. from Oxford University.

Organization Position Status
Acusphere, Inc. Executive Consultant Current
Dupont Merck Vice President Business Development and Marketing Former
University of Glasgow B.Sc. Former
University of Oxford D.Phil. Former
Organization Position Status
Acusphere, Inc. Board of Directors Current
Organization Position Status
Ftventures Limited Partner, Business Development, Head Current
Acusphere, Inc. Director Current
Dain Bosworth, Inc. Vice President Former
Montgomery Securities Senior Managing Director Former
Montgomery Securities Partner Former
Montgomery Securities Director of Private Equity Former
Bogle & Gates Attorney Former
Pomona College BA Former

Garen Bohlin, has served as one of our directors since 2005. Mr. Bohlin is the Chief Operating Officer for Sirtris Pharmaceuticals, Inc. in Cambridge, M.A. Previous to Sirtris, Mr. Bohlin served as President and CEO of Syntonix Pharmaceuticals, Inc. Prior to joining Syntonix, Mr. Bohlin was Executive Vice President of Genetics Institute where he was responsible for essentially all of the non-scientific areas that comprised approximately half of the then 1600 employees. Mr. Bohlin spent 14 years in executive management at Genetics Institute managing significant growth and playing a leading role in the closing of a broad range of financings. Prior Mr. Bohlin's tenure at Genetics Institute he spent 13 years at Arthur Andersen & Co. In addition to serving on Acusphere's Board, he is also a member of the Board of Directors of Targanta Pharmaceuticals, Inc.

Organization Position Status
Sirtris Pharmaceuticals, Inc. Coo Current
Acusphere, Inc. Director Current
Syntonix Pharmaceuticals, Inc. Chief Executive Officer Former
Syntonix Pharmaceuticals, Inc. President Former
Genetics Institute, Inc. Executive Vice President Former

Since July 2004, Mr. Greenacre has served as Chairman of Beijing Med-Pharm Corporation, a pharmaceutical company. Mr. Greenacre also has served since 2002 as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company. From 1997 to 2001, Mr. Greenacre served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company. From 1993 to 1997, Mr.

Organization Position Status
Life Mist Technologies, Inc. Chairman Current
Curis, Inc. Chair Current
BMP Sunstone Corporation Chairman of the Board Current
Lifemist Chairman Current
Pathway 2 Curis Board of Directors Current
Personalized Medicine Coalition Board of Directors Current
Cephalon, Inc. Board of Directors Current
Acusphere, Inc. Director Current
BMP Sunstone Corporation Committee Member Current
GlaxoSmithKline Plc Chairman Former
Creative BioMolecules, Inc. Director Former
BMP Sunstone Corporation Board of Directors Former
Curis, Inc. Director Former
Orchestra Therapeutics, Inc. Director Former

Sandra L. Fenwick, has served as one of our directors since 2004. Ms. Fenwick is Chief Operating Officer of the world-renowned Children's Hospital in Boston, Massachusetts. Prior to joining Children's Hospital in 1999, Ms. Fenwick was Senior Vice President of System Development for CareGroup, Inc. Before its merger with CareGroup, Ms. Fenwick served at Beth Israel Hospital for 20 years in various areas of increasing responsibility including Vice President and Deputy Director, Vice President of Clinical Services Planning and Development and Vice President of Network Development for Beth Israel Healthcare.

Organization Position Status
Children's Hospital Chief Operating Officer Current
Acusphere, Inc. Board of Directors Current
CareGroup, Inc. Senior Vice President of System Development Former

Executive News

  • Acusphere, Inc. Announces Amended Terms of Cephalon Agreements

    Forbes.com - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical's Scientific Advisory Board

    Pharma Live - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical’s Scientific Advisory Board

    Freshnews.com - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical's Scientific Advisory Board

    Street Insider - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedicals Scientific Advisory

    Business Wire via MSN Money - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical's Scientific Advisory Board

    RBC Dain Raushcer - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedicals Scientific Advisory Board

    Business Wire - 6/24/09 - View Story

  • Momenta Pharmaceuticals names new board member

    TradingMarkets - 6/15/09 - View Story

  • Momenta Pharmaceuticals, Inc. (MNTA) Announces Appointment of Bruce L. Downey to Board of Directors

    BioSpace - 6/12/09 - View Story

  • Momenta Pharmaceuticals Announces Appointment of Bruce L. Downey to Board of Directors

    Interest!ALERT - 6/12/09 - View Story

  • Momenta Pharmaceuticals Announces Appointment of Bruce L. Downey to Board of Directors

    Therapeutics Daily - 6/12/09 - View Story

  • Momenta Pharma names Bruce Downey to board, effective June 11 -Quick Facts

    RTTNews.com - 6/12/09 - View Story

  • Momenta Pharmaceuticals Announces Appointment of Bruce L. Downey to Board of Directors

    Yahoo! Canada - 6/12/09 - View Story

advertisement
     ACUS $0.14 +0.01 (7.69% )
Average Volume 1,159,880
Shares Outstanding 49.51M
Market Cap 6.9M
Year High 0.8
Year Low 0.02
Earnings Per Share N/A
P/E Ratio -
Dividend N/A
Yield N/A
Glass Door

Pharma Industry Companies

Company Employer Rating
Pfizer 3.0
advertisement